Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Zeller

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of Neurology|March 30, 2019
Prognostic factors in ALS: a comparison between Germany and ChinaJohannes Dorst, Lu Chen, Angela Rosenbohm, et al.
The Lancet. Neurology|October 18, 2024
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trialJan C Koch, Andreas Leha, Helen Bidner, et al.
Brain Communications|May 24, 2023
Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosisWolfgang P Ruf, Matej Boros, Axel Freischmidt, et al.
Brain : a Journal of Neurology|January 18, 2018
Hot-spot KIF5A mutations cause familial ALSDavid Brenner, Rüstem Yilmaz, Kathrin Müller, et al.
Neurological Research and Practice|July 3, 2024
Patients' and caregivers' perception of multidimensional and palliative care in amyotrophic lateral sclerosis - protocol of a German multicentre studyKatharina Linse, Constanze Weber, Peter Reilich, et al.
Journal of Neuromuscular Diseases|December 24, 2022
Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry StudyAstrid Pechmann, Max Behrens, Katharina Dörnbrack, et al.
Parkinsonism & Related Disorders|August 1, 2025
Validation of clinical ratings of cervical dystonia using computer-generated avatarsSebastian Loens, Roland Stenger, Feline Hamami, et al.
Journal of Neurology|February 27, 2024
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2Katharina Vill, Moritz Tacke, Anna König, et al.
The Lancet Regional Health. Europe|February 16, 2024
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational studyRené Günther, Claudia Diana Wurster, Svenja Brakemeier, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Neurology|March 30, 2019
Prognostic factors in ALS: a comparison between Germany and ChinaJohannes Dorst, Lu Chen, Angela Rosenbohm, et al.
The Lancet. Neurology|October 18, 2024
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trialJan C Koch, Andreas Leha, Helen Bidner, et al.
Brain Communications|May 24, 2023
Spectrum and frequency of genetic variants in sporadic amyotrophic lateral sclerosisWolfgang P Ruf, Matej Boros, Axel Freischmidt, et al.
Brain : a Journal of Neurology|January 18, 2018
Hot-spot KIF5A mutations cause familial ALSDavid Brenner, Rüstem Yilmaz, Kathrin Müller, et al.
Neurological Research and Practice|July 3, 2024
Patients' and caregivers' perception of multidimensional and palliative care in amyotrophic lateral sclerosis - protocol of a German multicentre studyKatharina Linse, Constanze Weber, Peter Reilich, et al.
Journal of Neuromuscular Diseases|December 24, 2022
Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry StudyAstrid Pechmann, Max Behrens, Katharina Dörnbrack, et al.
Parkinsonism & Related Disorders|August 1, 2025
Validation of clinical ratings of cervical dystonia using computer-generated avatarsSebastian Loens, Roland Stenger, Feline Hamami, et al.
Journal of Neurology|February 27, 2024
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2Katharina Vill, Moritz Tacke, Anna König, et al.
The Lancet Regional Health. Europe|February 16, 2024
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational studyRené Günther, Claudia Diana Wurster, Svenja Brakemeier, et al.
Pageof 7